品牌分类
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
商品描述
| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 1x2h,1x30min,1x30min |
| Standardrange | 0,016-3.609µg/L |
| Specimen/Volumes | 5µLSerum,Plasma |
| Substrate/isotope | TMB,450nm |
| RegulatoryStatus: | EU:CE |
Detailsfor:IGF-IIELISA
IBL我们的液体处理专业知识可实现高度复杂的分子诊断技术的可靠自动化，例如细胞遗传学（核型分析和FISH）和分子细胞遗传学（aCGH /阵列比较基因组杂交），其应用范围从代谢疾病和癌症到生殖遗传学和移植药物。该产品组合涵盖了细胞遗传学和分子细胞遗传学工作流程的关键阶段，从标准化工作站，经过验证的应用程序和专用用户界面，到与Tecan Labwerx合作开发的高度定制的平台。 TheIGF-IIELISAiscalibratedagainsttheInternationalStandard:WHONIBSC96/538.
ThestandardsoftheELISAarehumanIGF-IIinconcentrations0.45;1.5;3;5.63and9ng/ml,respectivelytheassayrangecovers–atrecommendednormalsampledilution-therangeto2400ng/ml.Byvaryingthesampledilutionthiscanbeadaptedtothespecialindividualrequirements.
Sensitivity
TheanalyticalsensitivityoftheELISAyields0.02ng/ml(2SDofzerostandardin20folddetermination).
TheInter-andIntra-Assayvariationcoefficientsarelessthan7.2%and6.6%respectively.
INTENDEDUSE
Scientificinvestigationsinthefieldofneonatalhypertrophy(IGF-IIisafoetalgrowthfactor)andmalignancies(IGF-IIisamonogenicgrowthfactor).
IGF-IIseemstobeofuseindifferentialdiagnosticsofmalignancies.Thus,itispossIBLetodifferentiatebyIGF-IIbetweenadrenocorticalcarcinomasandadenomas.FurthertumorstaginganddifferentiationbetweenhyperplasiaandcarcinomacanbeimprovedbyIGF-IImeasurementsinprostatetumors.TheIGF-Systemseemtobeofrelevanceinneurodegenerationaswell,e.g.Alzheimer´sandParkinson’sdiseases.
Theinsulin-likegrowthfactors(IGF)-Iand–IIplayapivotalroleintheregulationofproliferationanddifferentiationofseveraltissuetypes.IGF-IalsocalledSomatomedinChasamolecularweightof7.469kDa.ItsexpressionismainlyregulatedbyGrowthHormoneandnutrition.ButseveralhormonesandpeptidefactorsareknowntoinfluenceIGF-IIsynthesisindifferenttissues.BioavailABIlityoftheIGFsisregulatedbyspecificbindingproteins(IGFBP).BesidethehighaffinityInsulin-likeGrowthFactorBindingProteins1-6,IGFsarealsoboundbeIGFBP-relatedProteins.ThesebindingproteinsbindIGF-IandIGF-IIwiththesameaffinityorpreferIGF-II.DirectmeasurementofIGFsinserumsampleswithoutpretreatmentresultsinfalsevaluesbecauseoftheextremelyslowdissociationoftheIGF/IGFBPcomplexesduringtheassayincubationonlyapartoftheIGF-IIinthespecimencanbindtotheantibodiesandbedetected.
Therefore,varioustechniqueswereappliedtophysicallyseparateIGF-IIfromitsbindingproteinsbeforemeasurement,including(a)sizeexclusionchromatographyunderacidicconditions,(b)solid-phaseextractionand(c)acid-ethanolextraction.Thesetechniques,however,areeitherinconvenientortime-consumingorgiveincompleteandnot-reproduciblerecoveries.
Thisassayiseasy,fastandresultsdonotdependonthebindingproteinconcentrationofthesample.ItisbasedonthehighspecificityoftheemployedantibodiesforIGF-II.Thereisvirtuallynocross-reactivitywithIGF-I.ThisallowstheseparationofIGF-IIfromthebindingproteinsbyacidificationandblockingofthefreebindingproteinswithIGF-I.Thus,theendogenousIGF-IIisfreeinsolution.
ForconcretedatapleaseconsulttheInstructionforUseinthedownloadboxontherightside.ThestandardsoftheELISAarehumanIGF-IIinconcentrations0.45;1.5;3;5.63and9ng/ml,respectivelytheassayrangecovers–atrecommendednormalsampledilution-therangeto2400ng/ml.Byvaryingthesampledilutionthiscanbeadaptedtothespecialindividualrequirements.
Sensitivity
TheanalyticalsensitivityoftheELISAyields0.02ng/ml(2SDofzerostandardin20folddetermination).
TheInter-andIntra-Assayvariationcoefficientsarelessthan7.2%and6.6%respectively.
INTENDEDUSE
Scientificinvestigationsinthefieldofneonatalhypertrophy(IGF-IIisafoetalgrowthfactor)andmalignancies(IGF-IIisamonogenicgrowthfactor).
IGF-IIseemstobeofuseindifferentialdiagnosticsofmalignancies.Thus,itispossIBLetodifferentiatebyIGF-IIbetweenadrenocorticalcarcinomasandadenomas.FurthertumorstaginganddifferentiationbetweenhyperplasiaandcarcinomacanbeimprovedbyIGF-IImeasurementsinprostatetumors.TheIGF-Systemseemtobeofrelevanceinneurodegenerationaswell,e.g.Alzheimer´sandParkinson’sdiseases.
Theinsulin-likegrowthfactors(IGF)-Iand–IIplayapivotalroleintheregulationofproliferationanddifferentiationofseveraltissuetypes.IGF-IalsocalledSomatomedinChasamolecularweightof7.469kDa.ItsexpressionismainlyregulatedbyGrowthHormoneandnutrition.ButseveralhormonesandpeptidefactorsareknowntoinfluenceIGF-IIsynthesisindifferenttissues.BioavailABIlityoftheIGFsisregulatedbyspecificbindingproteins(IGFBP).BesidethehighaffinityInsulin-likeGrowthFactorBindingProteins1-6,IGFsarealsoboundbeIGFBP-relatedProteins.ThesebindingproteinsbindIGF-IandIGF-IIwiththesameaffinityorpreferIGF-II.DirectmeasurementofIGFsinserumsampleswithoutpretreatmentresultsinfalsevaluesbecauseoftheextremelyslowdissociationoftheIGF/IGFBPcomplexesduringtheassayincubationonlyapartoftheIGF-IIinthespecimencanbindtotheantibodiesandbedetected.
Therefore,varioustechniqueswereappliedtophysicallyseparateIGF-IIfromitsbindingproteinsbeforemeasurement,including(a)sizeexclusionchromatographyunderacidicconditions,(b)solid-phaseextractionand(c)acid-ethanolextraction.Thesetechniques,however,areeitherinconvenientortime-consumingorgiveincompleteandnot-reproduciblerecoveries.
Thisassayiseasy,fastandresultsdonotdependonthebindingproteinconcentrationofthesample.ItisbasedonthehighspecificityoftheemployedantibodiesforIGF-II.Thereisvirtuallynocross-reactivitywithIGF-I.ThisallowstheseparationofIGF-IIfromthebindingproteinsbyacidificationandblockingofthefreebindingproteinswithIGF-I.Thus,theendogenousIGF-IIisfreeinsolution.
